HRAS and thyroid gland carcinoma: He helped in the treatment of H-RAS-driven tumors with FTIs and in targeting the adaptive responses of BRAF or RAS-mutant thyroid cancers to RAF/MEK inhibitors with bispecific antibodies to TSHR and/or HER2.